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Abstract Biomarkers are important tools in clinical
diagnosis and prognostic classiWcation of various cuta-
neous malignancies. Besides clinical and histopatho-
logical aspects (e.g. anatomic site and type of the
primary tumour, tumour size and invasion depth, ulcer-
ation, vascular invasion), an increasing variety of
molecular markers have been identiWed, providing the
possibility of a more detailed diagnostic and prognostic
subgrouping of tumour entities, up to even changing
existing classiWcation systems. Recently published gene
expression or proteomic proWling data relate to new
marker molecules involved in skin cancer pathogene-
sis, which may, after validation by suitable studies, rep-
resent future prognostic or predictive biomarkers in
cutaneous malignancies. We, here, give an overview on
currently known serologic and newer immunohisto-
chemical biomarker molecules in the most common
cutaneous malignancies, malignant melanoma, squa-
mous cell carcinoma and cutaneous lymphoma, partic-
ularly emphasizing their prognostic and predictive
signiWcance.
Keywords Skin cancer · Biomarker · Prognosis · 
Serum · Immunohistochemistry
Introduction
Biomarkers play an important role in the diagnosis
and prognostic classiWcation of various cancer entities
and can moreover be useful in monitoring the
patient’s clinical course of disease and response to
therapy. In general, biomarkers are proteins, less
often carbohydrates or lipids, and their expression
proWles are associated with malignant disease. In the
majority of cases, the marker molecules are expressed
by the tumour cells themselves or by cells of the
tumour microenvironment. Thus, most biomarkers
can primarily be found in malignant tissues, but after
active secretion or passive release at tumour cell
destruction also become detectable in body Xuids like
blood, lymph or urine.
Besides morphological and histopathological bio-
markers (anatomic site and type of the primary
tumour, tumour size and invasion depth, ulceration,
vascular invasion), an increasing variety of molecular
markers have been identiWed, providing the possibility
of a more detailed diagnostic and prognostic subgroup-
ing of tumour entities, up to even changing existing
classiWcation systems. Recently published gene expres-
sion, as well as proteomic proWling data, indicates new
candidate molecules involved in skin cancer pathogen-
esis, which may after further validation represent new
markers superior to existing ones. This ongoing pro-
cess of biomarker identiWcation and validation would
result in a rapidly changing molecular view and classiW-
cation of skin cancers.
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Malignant melanoma
Serologic markers of malignant melanoma
Despite numerous therapeutic options, the prognosis
of malignant melanoma, once metastasized, is still
poor. Thus, the search for reliable methods to detect
metastases as early as possible and to identify patients
with high risk of disease progression is of major impor-
tance. The serological parameters most widely used for
the early detection of a tumour relapse or metastasis in
the follow-up of melanoma patients are the melanocyte
lineage/diVerentiation antigens S100-beta and mela-
noma inhibitory activity (MIA) (see Table 1 and
Fig. 1). Both proteins are with high, but not exclusive,
speciWcity expressed by melanoma cells and thus corre-
late with the patient’s tumour load.
The S100 protein is a 21-kDa thermo-labile acidic
dimeric protein, which was originally isolated from the
central nervous system (CNS) [49]. It consists of two
subunits, alpha and beta, in the combinations alpha/
alpha, alpha/beta and beta/beta. S100 aVects the assem-
bly and disassembly of microtubules and also interacts
in a calcium-dependent manner with the p53 tumour
suppressor gene. The beta subunit is expressed in cells
of the central nervous system as well as in cells of the
melanocytic lineage. Therefore, S100-beta measured in
the cerebrospinal Xuid was known as a marker of CNS
damage [59], years before S100-beta was shown to be a
useful serum marker in melanoma [30]. MIA was origi-
nally detected in melanoma cell culture supernatant [9]
and was shown to exert an important role in cell–
matrix interaction and metastasis [8].
Serum S100-beta has been shown to be superior
compared to MIA, as an early indicator of tumour pro-
gression, relapse or metastasis [18, 43], and its distribu-
tion as a serum biomarker of melanoma, therefore, is
the broadest [36]. Both markers have been shown to be
useful prognostic markers in melanoma patients with
distant metastases (stage IV, classiWcation system of
the American Joint Committee on Cancer, AJCC, see
Table 1 Serologic markers of malignant melanoma
Serologic marker Selected literature
Melanocyte lineage/diVerentiation 
antigens
S100-beta [30, 71, 32, 33, 18, 43, 28]
MIA (melanoma inhibitory activity) [9, 8, 10, 74, 28]
Tyrosinase [2]
5-S-Cysteinyldopa [91, 34]
L-Dopa/L-tyrosine [75]
Proangiogenic factors VEGF (vascular endothelial growth factor) [83, 56, 12]
BFGF (basic Wbroblast growth factor) [83, 12]
IL-8 (Interleukin-8) [68, 83, 12]
Molecules involved in cell adhesion 
and motility
sICAM-1 (soluble intracellular adhesion molecule 1) [34, 87, 94]
sVCAM (soluble vascular cell adhesion molecule 1) [26, 87]
Matrix metalloproteinases (MMP)-1 and 9 [63, 53]
Cytokines and cytokine receptors IL-6 (Interleukin-6) [50, 73]
IL-10 (Interleukin-10) [21, 51]
sIL-2R (soluble interleukin-2-receptor) [11, 58]
HLA molecules sHLA-DR (soluble HLA-DR) [62]
sHLA-class-I (soluble HLA-class I) [89]
Others LDH (lactate dehydrogenase) [72, 18, 6]
CRP (C-reactive protein)  [19]
Albumin [72]
TuM2-PK (Tumour pyruvate kinase type M2) [81]
sFas/CD95 [84]
YKL-40 [69, 70]
CYT-MAA (cytoplasmic melanoma-associated antigen) [85]
HMW-MAA (high-molecular-weight 
melanoma-associated antigen)
[85]
Fig. 1 Schematic presentation of the cellular localization and
function of the melanoma biomarkers S100-beta, tyrosinase and
melanoma inhibitory activity (MIA)Arch Dermatol Res (2007) 298:469–477 471
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Fig. 2) [71, 33], but fail to provide prognostic signiW-
cance in early stages of melanoma, especially in
patients who are tumour-free after surgical procedures
[74]. Because of the strong correlation of their serum
concentrations with the patients’ tumour load, S100-
beta and MIA are useful markers in the monitoring of
therapy response in advanced metastatic melanoma
patients (AJCC stage IV) [32]. Again, none of both
markers are suitable indicators of therapy response in
tumour-free early-stage melanoma patients (AJCC
stage II or III). Moreover, S100-beta has been shown
to fail to identify patients with lymph node microme-
tastases detected by sentinel node procedure [1].
The strongest prognostic serum biomarker in
advanced metastatic melanoma is lactate dehydroge-
nase (LDH), an unspeciWc marker indicating high
tumour load in a variety of tumour entities, including
melanoma. Studies comparing LDH, S100-beta and
MIA using multivariate data analysis showed LDH to
be the strongest independent prognostic factor in stage
IV melanoma patients [18]. Due to its high prognostic
signiWcance, coupled with its easy, cost-eYcient and
widely distributed detection methodology, serum LDH
is the only molecular marker that has been included in
the current melanoma staging and classiWcation system
of the AJCC [6]. It, moreover, serves as a stratiWcation
parameter in most randomized therapy trials per-
formed in stage-IV melanoma and may also be used to
monitor therapy response in these patients.
A variety of other molecules of peripheral blood
have been described as markers of tumour load and
disease progression in melanoma. These biomarkers
are derived from diVerent Welds like melanocytic diVer-
entiation (e.g. tyrosinase; see Fig. 1), tumour angiogen-
esis (e.g. VEGF, bFGF, IL-8), cell adhesion and
motility (e.g. ICAM-1, MMPs), cytokines and their
receptors (e.g. IL-6, IL-10), antigen presentation (e.g.
HLA molecules), tumour cell metabolism (e.g. TuM2-
PK), apoptosis (e.g. Fas/CD95) and many others (see
Table 1). However, neither one of these markers could
be conWrmed to be superior to S100-beta or LDH in
reXecting the prognosis of patients in advanced disease
stages, nor could any marker be shown to be of strong
prognostic relevance in early stage tumour-free
patients.
The serum proteomic proWling is an innovative
approach to identify new, potentially better serological
biomarkers in melanoma. This methodology oVers the
possibility of screening the whole serum proteome for
markers, which match diVerent criteria like prognostic
signiWcance, prediction of therapy response, etc. Using
this technology, marker proteins from thematic Welds,
diVerent from the above-mentioned ones, might be
found and thereafter validated for their clinical use.
The Wrst promising results have been obtained and are
currently tested in large sets of serum samples [46].
Immunohistochemical markers of malignant 
melanoma
Cutaneous malignant melanoma regularly develops
from the radial to the vertical growth phase and there-
after to metastatic disease. The variability of this clini-
cal course is only partially explained by morphological
and histopathological parameters like primary tumour
localization, patient gender and age, mitotic rate,
tumour thickness and ulceration. There is a need to
identify molecular variables, which help to assign
patients to speciWc risk groups. The number of modali-
ties for diagnosing and subclassifying malignant mela-
nomas is rapidly increasing and includes
immunohistochemistry of tissue sections and micro-
arrays, gene expression proWling, comparative genomic
hybridization and mutational analysis. These method-
ologies promise to improve our prognostic classiWca-
tion systems, as well as our diagnostic and therapeutic
potential.
For diagnostic purposes, a small panel of melanocytic
lineage markers, e.g. S100, MART-1/MelanA and
gp100/HMB45, is suYcient to distinguish melanoma
from non-melanocytic cancers. For the diVerentiation
between benign and malignant melanocytic lesions, a
Fig. 2 Kaplan–Meier survival curves of 65 patients with ad-
vanced metastatic melanoma (AJCC stage IV). Patients with ele-
vated serum levels of S100-beta show a signiWcantly reduced
survival probability compared to patients with normal S100-beta
serum concentrations (P = 0.003 by log rank test; detection sys-
tem LIAISON Sangtec 100)472 Arch Dermatol Res (2007) 298:469–477
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review of immunohistochemical markers is given in ref.
[44]. The present review focuses on newer markers with
potential prognostic impact for the disease. For this pur-
pose, the situation is more complex. The transformation
from benign melanocytes to metastatic melanoma is the
result of a compilation of genetic alterations crucial to
cell division, diVerentiation, anti-apoptosis, invasion,
angiogenesis and sustenance in a microenvironment dis-
tant from the point of origin of the cell. Several marker
molecules involved in these genetic alterations have
been identiWed, and their expression in primary mela-
noma has been studied and correlated with the progno-
sis. Table 2 gives a current overview on already
identiWed biomarkers, whose abnormal expression is
associated with the patient’s prognosis. It may be
expected that the most detailed prognostic classiWcation
will result not from one, but rather from a panel of mul-
tiple biomarkers from this list.
In a recent retrospective study, frozen tissue samples
from primary melanomas with long-term clinical
Table 2 Immunohistochemical markers of malignant melanoma associated with prognosis
Association with poor prognosis Selected literature
Melanocyte lineage/DiVerentiation antigens
gp100/HMB45 Increased expression [52]
Tumour suppressors/oncogenes/signal transducers
p16 INK4A Decreased expression [47, 3]
PTEN Decreased expression [48]
pRb (retinoblastoma protein) Inactivation due to protein 
phosphorylation
[65]
EGFR (epidermal growth factor receptor) Increased expression [80]
p-Akt (activated serine-threonine protein kinase B) Increased expression [17]
c-Kit Expression [35, 82]
c-myc Increased expression [42]
AP-2 (activator protein-2alpha) transcription factor Loss of nuclear AP-2 expression [7]
HDM2 (human homologue of murine mdm2) Increased expression [61]
bcl-6 Expression [3]
Cell cycle associated proteins
Ki67 (detected by Mib1) Increased expression [29, 3, 57]
Cyclin A, B, D, E Increased expression [24, 25]
p21CIP1 Decreased expression [3]
Geminin Increased expression [92]
PCNA (proliferating cell nuclear antigen) Increased expression [92]
Regulators of apoptosis
bcl-2 Increased expression [78]
bax Decreased  expression [23]
Bak Decreased expression [23]
APAF-1 (Apoptotic protease activating factor-1) Decreased expression [27]
Surviving Increased expression [78]
Molecules involved in angiogenesis
LYVE-1 (lymphatic vascular endothelial 
hyaluronan receptor-1) 
Increased expression [16]
PTN (pleiotrophin) Increased expression [93]
Molecules involved in cell adhesion and motility
P-Cadherin Strong cytoplasmic expression [5]
E-Cadherin Decreased expression [4]
Beta-catenin Loss of nuclear staining [5]
Integrins beta1 and beta3  Increased expression [66]
MMPs (matrix metalloproteinases) Increased expression [63]
Dysadherin Increased expression [54]
CEACAM1 (carcinoembryonic-antigen-related 
cell-adhesion molecule 1)
Increased expression [79]
Osteonectin (also termed BM40 or SPARC 
(secreted protein, acidic and rich in cysteine))
Increased expression [45]
Others 
TA (telomerase activity)  Increased expression [13]
Melastatin Decreased expression [22]
ALCAM/CD166 
(Activated leukocyte cell adhesion molecule)
Increased expression [77]
CXCR4 receptor Increased expression [67]
Metallothionein Increased expression [88]Arch Dermatol Res (2007) 298:469–477 473
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follow-up were analysed using a pangenomic oligonu-
cleotide microarray [92]. The authors describe a signa-
ture of 174 genes, identifying patients at risk to develop
distant metastasis. From these 174 genes, 141 were
under-expressed and 33 were over-expressed in pri-
mary melanomas of patients who remained free of
metastasis for 4 years. About 30 of these 174 genes
have already been studied in melanoma and include
genes involved in cell cycle (CKS2, CDC2, CCNB1,
CENPF and DHFR), mitosis (HCAP-G and STK6),
mitotic spindle checkpoint (BUB1), inhibition
(BIRC5) or stimulation (GPR105) of apoptosis, DNA
replication (TOP2A, RRM2, TYMS, PCNA, MCM4
and MCM6), stress response (GLRX2, DNAJA1,
HSPA4, HSPA5, HSPD1 and TXNIP), ubiquitin cycle
(SIP), actin and calmodulin binding (CNN3), intracel-
lular signalling (STMN2), negative regulation of the
Wnt signaling pathway (CTNNBIP1), inhibition of
MITF expression (EMX2), regulation of proteolysis
(TNA), testis cancer (CML66) and metastasis suppres-
sion (NME1). Winnepenninckx et al. [92] recommend
the use of a battery of antibodies that may improve the
future determination of prognosis and treatment strati-
Wcation. The determination of karyopherin-alpha2,
MCMs (minichromosome maintenance proteins), gem-
inin and PCNA over-expression could be used for
screening in melanoma patients with a poor clinical
outcome.
Squamous cell carcinoma of the skin
While primary cutaneous squamous cell carcinomas
(SCC) are usually easily treatable, they have the poten-
tial to recur locally and even metastasize, then leading
to a signiWcant morbidity and mortality. Therefore, it is
important to identify those tumours that are more
aggressive and require closer follow-up and additional
treatments, such as lymph adenectomy or radiation
therapy. Established prognostic factors include ana-
tomic site of primary, tumour size, depth of invasion,
rapid growth, grade of diVerentiation, perineural inva-
sion, history of previous treatment, host immunosup-
pression, and etiologic factors such as burn scars,
radiation and chronic ulceration. The histological sub-
types of SCC have also been considered as a factor in
determining the prognosis [60].
Only few molecular markers are known to be associ-
ated with progression or prognosis of cutaneous SCC.
In the following, we give an overview on some recently
described proteins whose abnormal expression contrib-
utes to a malignant phenotype in this cancer entity.
STAT3, a member of the signal transducer and
activator of transcription (STAT) family of transcrip-
tion factors is a known regulator of cell motility. The
expression of phosphorylated STAT3 (p-STAT3) was
described to be stronger in poorly diVerentiated than in
well-diVerentiated SCCs. Moreover, the percentage of
tumour cells expressing p-STAT3 correlated with the
depth of tumour invasion and with metastasis forma-
tion [76].
E-Cadherin is a Ca(2+)-dependent, intercellular
adhesion molecule that is speciWcally expressed in epi-
thelial cells and tissues and functions by maintaining
intercellular connections. In some types of carcinomas,
E-cadherin expression of tumour cells is decreased in
association with metastasis. In cutaneous SCC, a
decreased expression of E-cadherin in the primary
lesion is correlated with the development of regional
lymph node metastasis [41]. Additionally, a decreased
expression is more often associated with well-diVeren-
tiated than with poorly diVerentiated SCC. Therefore,
E-cadherin might be useful as a marker for the meta-
static potential of well-diVerentiated SCC [41]. The
simultaneous detection of p-STAT3 and E-cadherin
may contribute to the prediction of prognosis of cuta-
neous SCC patients [76].
Another marker to distinguish between well-diVer-
entiated and poorly diVerentiated SCC is Ets-1 [37].
Ets-1 is a transcription factor regulating the expression
of various genes including matrix metalloproteinases
(MMPs). Therefore, Ets-1 might be important in the
pathogenesis of invasive SCC. MMP-12 was found to
be expressed by tumour cells in squamous cell carci-
noma of the vulva. Its expression correlates with inva-
siveness, while that of macrophages predict a better
clinical outcome [38]. A cell surface marker, CD44, is a
glycoprotein widely distributed in the extracellular
matrix. CD44 isoforms, which arise from alternative
mRNA splicing, were found to be implicated in the for-
mation of tumour metastasis. In a study by Rodriguez-
Rodriguez et al., it was shown that lymph node metas-
tases of cutaneous SCC of the vulva were immunoreac-
tive for CD44–9v [64]. Also, CD44–10v expression was
present in 78% of tumours compared to only 56% of
normal epithelium. CD44–10v membrane expression,
but not cytoplasmic expression, correlates with disease
recurrence [64]. In ocular squamous cell carcinomas,
over-expression of CD44–6v is correlated with tumour
progression and metastasis [55].
Cutaneous T-cell lymphomas
Cutaneous T-cell lymphomas (CTCL) are a heteroge-
neous group of cutaneous non-Hodgkin’s lymphomas.474 Arch Dermatol Res (2007) 298:469–477
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In this cutaneous malignancy, the tumour cells home to
and persist in the skin, producing a broad spectrum of
clinical entities. The prognosis of CTCL depends on
histologic and molecular aspects. The new WHO/
EORTC classiWcation for cutaneous lymphomas com-
prises mature T-cell and natural killer (NK)-cell lym-
phomas, mature B-cell lymphomas and immature
haematopoietic malignancies. Marker proteins for the
diagnosis of CTCL include, for example, CD2, CD3,
CD4, CD5, CD7, CD8, CD14, CD16/56, CD19, CD25,
CD45, CD45RA and CD45R0 [90].
The probability of survival in CTCL can be accu-
rately predicted by a formula based on the clinical
CTCL-Severity-Index (CTCL-SI) [20], which evaluates
the involvement of the skin, lymph nodes, blood and
visceral organs [40]. Besides clinical and morphological
parameters, several molecules have been investigated
in CTCL that are involved in general cellular signalling
processes, regulation of cellular proliferation and
apoptosis, like Jun, Myc, c-myb, p53, STATs, bcl-2,
Fas/CD95 and SOCS-3, or contribute to the putative
immunopathology of the disease such as expression of
inhibitory MHC receptors (ILT2/CD85j), NK recep-
tors (p140/KIR3DL2) and dendritic cell defects
(CD40). The abnormal expression of these molecules
could be relevant for the prognosis of CTCL, as it has
been shown for other tumour entities [39].
With regard to serological biomarkers in CTCL, it
has been shown that the serum concentrations of the
soluble alpha-chain of the interleukin-2 receptor (sIL-
2R) as well as lactate dehydrogenase (LDH) strongly
correlate with lymph node size, but only sIL-2R signiW-
cantly correlates with the severity of skin manifesta-
tions in erythrodermic patients [86]. Moreover, sIL-2R
was demonstrated to be produced at a relatively low
rate by tissue-based lymphoma cells, whereas large-cell
transformation in CTCL results in a marked increase in
the sIL-2R production in some patients [86]. In addi-
tion to sIL-2R, neopterin and beta2-microglobulin
have been shown to be signiWcantly elevated in the
serum from patients with Sezary syndrome. Thus, sIL-
2R seems to be the most sensitive marker, which is typ-
ically increased in Sezary syndrome. Concerning the
outcome of the disease, in terms of disease progression
versus non-progression, only neopterin showed a sig-
niWcant prognostic value in non-leukemic CTCL
patients [31].
Conclusion and future directions
Taken together, molecular markers provide additional
and much more detailed information for the prognostic
classiWcation of cutaneous malignancies. Currently, this
is particularly true for malignant melanoma, but will
certainly also aVect other entities in due time. In addi-
tion to the serological and immunhistochemical bio-
markers discussed here, genetic abnormalities have
recently been recognized to inXuence the prognosis of
cancer patients in higher extents than previously
assumed. With regard to malignant melanoma, a new
classiWcation system was proposed combining genetic
aberrations with histomorphological changes, result-
ing in new insights into the pathogenesis of this malig-
nancy [14,  15]. It may be expected that the rapidly
increasing knowledge of molecular mechanisms would
lead to mainly biomarker-based, rather than morphol-
ogy-based, classiWcation systems that might facilitate
an individualized, molecular-driven cancer therapy.
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